|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Microbial Influences in Inflammatory Bowel Diseases显示文摘 | R. Balfour Sartor | 2008 | Gastroenterology2008，，2： | 5 |
| 2 | Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: Summary of a symposium显示文摘 | Vishnudutt Purohit J. Christian Bode Christiane Bode David A. Brenner Mashkoor A. Choudhry Frank Hamilton Y. James Kang Ali Keshavarzian Radhakrishna Rao R. Balfour Sartor Christine Swanson Jerrold R. Turner | 2008 | Alcohol2008，，5： | 3 |
| 3 | Microbial Influences in Inflammatory Bowel Diseases显示文摘 | R. Balfour Sartor | 2008 | Gastroenterology2008，，2： | 2 |
| 4 | Targeting inflammation in pancreatic cancer: Clinical translation显示文摘Preclinical modelling studies are beginning to aid development of therapies targeted against key regulators of pancreatic cancer progression. Pancreatic cancer is an aggressive, stromally-rich tumor, from which few people survive. Within the tumor microenvironment cellular and extracellular components exist, shielding tumor cells from immune cell clearance, and chemotherapy, enhancing progression of the disease. The cellular component of this microenvironment consists mainly of stellate cells and inflammatory cells. New findings suggest that manipulation of the cellular component of the tumor microenvironment is possible to promote immune cell killing of tumor cells. Here we explore possible immunogenic therapeutic strategies. Additionally extracellular stromal elements play a key role in protecting tumor cells from chemotherapies targeted at the pancreas. We describe the experimental findings and the pitfalls associated with translation of stromally targeted therapies to clinical trial. Finally, we discuss the key inflammatory signal transducers activated subsequent to driver mutations in oncogenic Kras in pancreatic cancer. We present the preclinical findings that have led to successful early trials of STAT3 inhibitors in pancreatic adenocarcinoma. | Colin William Steele Nina Angharad Kaur Gill Nigel Balfour Jamieson Christopher Ross Carter | 2016 | World Journal of Gastrointestinal Oncology2016，8，4： | 2 |
| 5 | Future directions in inflammatory bowel disease management显示文摘 | Geert R. D’Haens R. Balfour Sartor Mark S. Silverberg Joel Petersson Paul Rutgeerts | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 6 | The Hedgehog Signalling Pathway in the Gastrointestinal Tract: Implications for Development, Homeostasis, and Disease显示文摘 | Charlie Lees Sarah Howie R. Balfour Sartor Jack Satsangi | 2005 | Gastroenterology2005，，5： | 2 |
| 7 | Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4显示文摘 | Dianne H. Dapito Ali Mencin Geum-Youn Gwak Jean-Philippe Pradere Myoung-Kuk Jang Ingmar Mederacke Jorge M. Caviglia Hossein Khiabanian Adebowale Adeyemi Ramon Bataller Jay H. Lefkowitch Maureen Bower Richard Friedman R. Balfour Sartor Raul Rabadan Robert | 2012 | Cancer Cell2012，，4： | 2 |
| 8 | Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria显示文摘 | Sandra C. Kim Susan L. Tonkonogy Carol A. Albright Julia Tsang Edward J. Balish Jonathon Braun Mark M. Huycke R. Balfour Sartor | 2005 | Gastroenterology2005，，4： | 2 |
| 9 | Etodolac a reappraisal of its pharmacology and therapeutic use in rheumatic disease and pain states显示文摘 | Balfour M Micaela T | 1991 | Drugs1991，42，2： | 1 |
| 10 | Acarbose:An update of its pharmacology and therapeutic use in diabetes metllitus显示文摘 | Balfour J A Mc Tavish D | 1993 | Drugs1993，46，6： | 1 |
| 11 | Factors influencing the life expectancy of patients operated on for gastric ulcer显示文摘 | Balfour DC | 1922 | Ann Surg1922，76，： | 1 |
| 12 | Periampullary diverticula and pancreaticobilliary disease显示文摘 | Lobo DN Balfour TW Iftikhar SY | 1999 | Brit J Sugr1999，86，： | 1 |
| 13 | Real-time top-face vision based control of weld pool size显示文摘 | Smith J S Balfour C | 2005 | Industrial Robot2005，32，4： | 1 |
| 14 | Perspectives for improving the evaluation and access of therapies for rare lung dis- eases in Europe显示文摘 | Luisetti M Balfour Lynn IM Johnson SR | 2012 | Respir Med2012，106，6： | 1 |
| 15 | A virologicpilot study of valacyclovir in infectious mononucleosis 显示文摘 | Balfour HH Hokanson KM Schacherer RM | 2007 | J ClinVirol2007，39，1： | 1 |
| 16 | Assessing Writing in MOOCs: Auto- mated Essay Scoring and Calibrated Peer Review 显示文摘 | Balfour S | 2013 | Research & Practice IN Assessment2013，，8： | 1 |
| 17 | Aearbose: an update of its pharmacology and ther- apeutic use in diabetes menitus 显示文摘 | Balfour JA Metavish D | 1993 | Drugs1993，46，6： | 1 |
| 18 | Use of the polymerase chain reaction to detect Toxoplasma gondii in human blood samples 显示文摘 | Ho-yen DO Jaw L Balfour AH | 1992 | J Clin Pathol1992，45，10： | 1 |
| 19 | Progressive versus catastrophic loss of the ability to walk: implications for the prevention of mobility loss显示文摘 | Guralnik JM Ferrucci L Balfour JL | 2001 | J Am Geriatr Soc2001，49，11： | 1 |
| 20 | Valacyclovir pharmacokinetics and exploratory pharmaeodynamics in young adults with Epstein-Barr virus infectious mononucleosis 显示文摘 | Vezina HE Balfour HH Jr Weller DR | 2010 | J Clin Pharmacol2010，50，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员